TCGA-44-7667-01A-31R-2066-07
— · cohortA3
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA3
- subtype
- cohortA3
- age_years
- 49
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.640
- MYC_TARGETS_V2+0.630
- MYC_TARGETS_V1+0.590
- G2M_CHECKPOINT+0.540
- DNA_REPAIR+0.380
- OXIDATIVE_PHOSPHORYLATION+0.320
- PANCREAS_BETA_CELLS+0.310
- SPERMATOGENESIS+0.270
- MTORC1_SIGNALING+0.230
- MITOTIC_SPINDLE+0.220
Top 10 suppressed
- TNFA_SIGNALING_VIA_NFKB-0.470
- IL6_JAK_STAT3_SIGNALING-0.450
- INTERFERON_ALPHA_RESPONSE-0.450
- INTERFERON_GAMMA_RESPONSE-0.450
- HEDGEHOG_SIGNALING-0.440
- INFLAMMATORY_RESPONSE-0.410
- TGF_BETA_SIGNALING-0.390
- ALLOGRAFT_REJECTION-0.380
- APOPTOSIS-0.360
- HYPOXIA-0.360
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | AUR-AG0N-TTM1-A-1-1-R-A743-41 | — | E | 0.949 |
| 2 | BS_R439VVPK | medulloblastoma | — | 0.946 |
| 3 | BS_HE57E1RP | medulloblastoma | — | 0.943 |
| 4 | BS_YETBN0RQ | medulloblastoma | — | 0.939 |
| 5 | BS_M84H3KXA | medulloblastoma | — | 0.937 |
| 6 | SRR12696795 | — | — | 0.934 |
| 7 | C3L-01285 | — | cohortSQ2 | 0.934 |
| 8 | SRR650205 | — | — | 0.931 |
| 9 | TCGA-55-7570-01A-11R-2039-07 | — | cohortA3 | 0.929 |
| 10 | BS_9NZ2D6AD | medulloblastoma | — | 0.928 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 13 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.640 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.630 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.590 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.540 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.380 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.320 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.310 | Cobimetinib | — uncovered |
| SPERMATOGENESIS | 0.270 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.230 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.220 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.210 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.130 | Inavolisib | — uncovered |
| PEROXISOME | 0.010 | Idelalisib | — uncovered |